Pfizer (NYSE:PFE) Stock Rating Lowered by Wall Street Zen

Key Points

• Pfizer has been downgraded from a "buy" to a "hold" rating by Wall Street Zen, reflecting a shift in analyst sentiment.
• Despite the downgrade, several other analysts have increased their price targets for Pfizer, with an average target price of $28.12.
• Pfizer reported strong earnings, exceeding analysts' expectations with $0.78 EPS and $14.65 billion in revenue for the latest quarter, indicating a 10.3% year-over-year growth.

Pfizer (NYSE:PFE - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research report issued to clients and investors on Sunday.

A number of other research analysts have also recently commented on PFE. Bank of America upped their price target on Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Morgan Stanley upped their price target on Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 6th. Finally, Citigroup upped their price target on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Pfizer presently has an average rating of "Hold" and a consensus target price of $28.12.

Pfizer Trading Up 0.6%

Shares of Pfizer stock opened at $23.75 on Friday. The business has a fifty day simple moving average of $24.55 and a two-hundred day simple moving average of $24.13. Pfizer has a 1 year low of $20.92 and a 1 year high of $30.43. The company has a market capitalization of $135.03 billion, a price-to-earnings ratio of 12.63, a P/E/G ratio of 0.77 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $14.65 billion for the quarter, compared to analysts' expectations of $13.43 billion. During the same quarter in the previous year, the business posted $0.60 earnings per share. The business's revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts forecast that Pfizer will post 2.95 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Brighton Jones LLC increased its stake in shares of Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock valued at $17,677,000 after purchasing an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC increased its stake in shares of Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock valued at $498,000 after purchasing an additional 2,087 shares in the last quarter. GAMMA Investing LLC increased its stake in Pfizer by 4,183.6% during the 1st quarter. GAMMA Investing LLC now owns 1,599,742 shares of the biopharmaceutical company's stock worth $40,537,000 after buying an additional 1,562,396 shares in the last quarter. Cascade Investment Advisors Inc. increased its stake in Pfizer by 2.0% during the 1st quarter. Cascade Investment Advisors Inc. now owns 64,409 shares of the biopharmaceutical company's stock worth $1,632,000 after buying an additional 1,265 shares in the last quarter. Finally, Fifth Third Wealth Advisors LLC increased its stake in Pfizer by 35.9% during the 1st quarter. Fifth Third Wealth Advisors LLC now owns 120,285 shares of the biopharmaceutical company's stock worth $3,048,000 after buying an additional 31,766 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.